Dialogues

Jun 22, 2024, 09:52

ASCO24 Updates: Is RANO classification the future of glioblastoma?

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video Philipp Karschnia, Neurosurgical Oncologist at Ludwig-Maximilians-University of Munich, Germany, shares insights about their poster on “Development and validation of a clinical risk score for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO Resect group.“

My name is Philipp Karschnia. I’m a neurosurgeon and a surgical neuro-oncologist from Munich in Germany. So, after surgery, which is the first step of therapy for patients with newly diagnosed glioblastoma, patients are frequently entering clinical trials and we know that exonerph resection matters in terms of outcome and we need to quantify exonerph resection to not introduce any prognostic imbalances between clinical trials and between study arms within an individual trial.

However, besides exonerph resection, there are certainly also other interactive factors to be considered, such as the patient’s function, the age, or molecular markers such as the MGMT promoter ventilation status. In our work, based on a cohort of more than 1,000 newly diagnosed glioblastoma patients, we developed a risk model which integrates all of those markers. So, exonerph resection measured per renal categories for exonerph resection, age, MGMT promoter ventilator status, and the functional status of the patient to develop risk categories.

And each individual patient can be classified based on the presence or absence of the prognostic factors into an individual risk category. And this risk category stratifies patients, whether they are at low, at intermediate, or at high risk for less favorable postoperative outcome. This risk model and the prognostic value of this risk model held true also in external validation cohort.

We entitled this risk model the RANO risk categories for postoperative outcome. So, response assessment and neuro-oncology, this is what RANO stands for. And we believe this might be an important tool to use in the clinical trial setting.

More videos and content from ASCO 2024 on OncoDaily.